NAMS - NewAmsterdam Pharma Co N.V.
31.18
0.775 2.486%
Share volume: 883,667
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$30.40
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-07-2024 | 11-06-2024 | 02-26-2025 | 05-08-2025 | 11-05-2025 | 02-18-2026 | |
| Assets | ||||||||
| Total Assets | 488.463 M | 446.690 M | 439.191 M | 864.620 M | 818.413 M | 786.427 M | 769.284 M | |
| Current Assets | 487.822 M | 445.352 M | 437.874 M | 863.413 M | 817.304 M | 732.328 M | 675.700 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 4.951 M | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 62.447 M | 60.057 M | 164.539 M | 146.239 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 481.147 M | 430.708 M | 422.729 M | 771.743 M | 748.420 M | 538.407 M | 490.002 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 53.091 M | 92.609 M | |
| Property Plant Equipment | 101.000 K | 234.000 K | 231.000 K | 242.000 K | 238.000 K | 323.000 K | 383.000 K | |
| Other Assets | 540.000 K | 1.104 M | 1.086 M | 965.000 K | 871.000 K | 53.776 M | 93.201 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 488.463 M | 446.690 M | 439.191 M | 864.620 M | 818.413 M | 786.427 M | 769.284 M | |
| Total liabilities | 76.660 M | 59.251 M | 60.329 M | 107.120 M | 41.050 M | 58.357 M | 85.853 M | |
| Total current liabilities | 59.726 M | 45.307 M | 41.255 M | 106.918 M | 40.913 M | 58.272 M | 85.787 M | |
| Accounts Payable | 18.506 M | 15.469 M | 17.619 M | 18.352 M | 14.108 M | 13.730 M | 24.392 M | |
| Other liabilities | 16.490 M | 13.722 M | 19.074 M | 202.000 K | 137.000 K | 85.000 K | 66.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 16.490 M | 13.722 M | 19.074 M | 202.000 K | 137.000 K | 85.000 K | 66.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 411.803 M | 387.439 M | 378.862 M | 757.500 M | 777.363 M | 728.070 M | 683.431 M | |
| Common stock | 818.121 M | 832.764 M | 840.834 M | 1.312 B | 1.371 B | 1.411 B | 1.441 B | |
| Retained earnings | -410.740 M | -449.747 M | -466.394 M | -558.571 M | -598.098 M | -687.467 M | -762.390 M |